

# Annual General Meeting of CombiGene 2019

Today, 16 May 2019, CombiGene AB (publ) held its Annual General Meeting (“AGM”) in Lund. Below follows a summary of the resolutions by the AGM. All decisions were made with the required majority.

## Dividend

The AGM resolved to adopt the profit and loss account and the balance sheet as well as the consolidated profit and loss account and the consolidated balance sheet. Furthermore, the AGM resolved that no dividend is to be paid for the financial year 2018.

## Resolution on discharge from liability for the Board Members and the CEO

The AGM resolved to discharge the Board Members and the CEO from liability for the financial year 2018.

## The Board of Directors, auditor and remuneration

The Board Members Arne Ferstad, Peter Nilsson, Lars Thunberg and Susana Ayesa Alvarez were re-elected and Hilde Furberg was elected as a new Board Member. Morten Albrechtsen declined to be re-elected. Arne Ferstad was re-elected Chairman of the Board. The AGM resolved that remuneration to the Board of Directors will be SEK 175,500 to the Chairman of the Board and SEK 114,400 each to the Board Members.

The chartered accountants Thomas Axelsson and Fatima Smiding were re-elected as auditors. The chartered accountant Joakim Paulson was re-elected as deputy auditor. The AGM resolved that remuneration to the auditors will be paid according to approved invoice.

## Resolution on authorisation for the Board of Directors to issue shares, convertibles or warrants

The AGM authorised the Board of Directors, in accordance with the proposal in the notice, to issue new shares, convertibles or warrants on one or more occasions prior to the next AGM, with or without regard to shareholders’ pre-emption rights. The payment of issued shares may be in cash, by non-cash consideration or by set-off.

---

## About CombiGene AB

CombiGene’s business concept is to develop effective gene therapies for treatment of difficult-to-treat diseases for which adequate treatment methods are currently lacking. The company intends to take its candidate drugs through the phases of preclinical development and initial clinical studies under its own management, and subsequently continue development and commercialization under its own management or in collaboration with other partners. Founded on the basis of scientific discoveries made at Lund University and the University of Copenhagen, CombiGene has offices at Medicon Village in Lund, Sweden. The company is public and listed on the Swedish marketplace Nasdaq First North and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 [info@fnca.se](mailto:info@fnca.se). For further information, please visit [www.combigene.com](http://www.combigene.com)

## For further information:

CombiGene AB (publ)  
Jan Nilsson, CEO  
Phone: +46 (0)704 66 31 63  
Email: [jan.nilsson@combigene.com](mailto:jan.nilsson@combigene.com)

**Please read MORE FROM THE COMPANY, a newsletter from CombiGene which contains general news and information that is judged not to have a significant effect on the share price. Other issues of MORE FROM THE COMPANY and press releases are available at [www.combigene.com](http://www.combigene.com)**

